We are live on ! Find out more
CELGZ

Celgene Corporation Contingent Value Rights

Delisted

CELGZ was delisted on the 29th of November, 2019.

22 hedge funds and large institutions have $1.25M invested in Celgene Corporation Contingent Value Rights in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% less capital invested

Capital invested by funds: $1.25M → $1.25M (-$6.77K)

15% less funds holding

Funds holding: 2622 (-4)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
22
Holders Change
-4
Holders Change %
-15.38%
% of All Funds
0.55%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
1
Reduced
3
Closed
4
Calls
Puts
Net Calls
Net Calls Change

CELGZ Hedge Fund Activity: Q1 2017 in Review

22 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q1 2017, worth a combined $1.25M — down 0.54% from $1.25M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CELGZ and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was Creative Planning, adding an estimated $1.09K. The largest seller was Citadel Advisors, exiting entirely with an estimated $23K sold.

  • 22 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q1 2017, down from 26 in Q4 2016.
  • Funds reported $1.25M of Celgene Corporation Contingent Value Rights stock for Q1 2017, down 0.54% quarter-over-quarter.
  • 1 fund opened new Celgene Corporation Contingent Value Rights positions in Q1 2017 and 4 closed out, a net change of -3 holders.
  • The largest Celgene Corporation Contingent Value Rights buyer in Q1 2017 was Creative Planning, an estimated $1.09K added.
  • The largest Celgene Corporation Contingent Value Rights seller in Q1 2017 was Citadel Advisors, an estimated $23K sold.

Based on aggregated 13F filings for Q1 2017.